HCV and cancer collection in Infectious Agents and Cancer

A new article collection focused on Hepatitis C virus and Cancer, has been launched in Infectious Agents and Cancer.


2014 was an important year for scientists working on Hepatitis C Virus (HCV) as it celebrated the 25th anniversary of its discovery and the establishment of new Interferon (IFN)-free therapeutic regimens able to eradicate HCV infections.

HCV isolation was achieved in Dr Houghton’s laboratory at Chiron Corporation in 1989, almost 20 years after the demonstration by Alter’s Laboratory at the NIH that most post-transfusion hepatitis cases were not due to hepatitis A or B viruses.

25 years later, new anti-HCV direct-acting antivirals have been developed and more than 130 million HCV-infected people finally have a chance of an effective cure.

The likely eradication of HCV infection will also drastically contribute to reduce the worldwide burden of hepatocellular carcinomas (HCC), the fifth most prevalent cancer type and the third cause of cancer deaths.

Moreover, such studies will likely contribute to the identification of specific HCC molecular pathways and novel molecular/immunotherapy targets.

Read the collection here.

Franco Buonaguro

Dr Buonaguro is the Editor-in-Chief of Infectious Agents and Cancer. He is currently the Director of Molecular Biology and Viral Oncology Unit, in the Department of Experimental Oncology at the Natl Cancer Institute “Fondazione Pascale”, Naples - Italy.

View the latest posts on the On Biology homepage

One Comment

Carol L. Hunt

What exactly is an anti viral outside of the fact the anti viral fights a virus? What is interferon? I am wondering how close is the chemical structure of HCV Hepatitis C and A to HSV-1 and HSV-2? Is hepatitis C undergoing permutations into Hepatitis A and then undergoing more permutations into HSV-1 and then undergoing more permutations into HSV-2 and the scientists are not seeing the chain of permutations?

Comments are closed.